Select Page

TARGETING AGGRESSIVE CANCER

Transforming cancer treatments and the lives of cancer patients by targeting the molecular pathways that drive the most aggressive and resistant forms of cancer.

OUR VISION

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer. In doing so, we aim to have a major impact on the lives of patients with the greatest unmet need and transform the way that cancer is treated.

OUR FOCUS

Our programmes are advanced through understanding the mechanisms that cause cancer and resistance allied with cutting-edge technologies to identify therapeutics and those who would most benefit from them. Through linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick Therapeutics will drive its portfolio of ground-breaking cancer therapies from laboratory to clinic.

OUR TEAM

A highly experienced and dedicated team with an outstanding track record of discovering and developing innovative cancer medicines; changing the treatment options for patients from non-selective chemotherapy to better tolerated targeted agents. The Carrick Therapeutics team have many examples of successful launches and commercial success and of strategies to target the right drug to the right patient.

OUR COLLABORATORS

Our network of collaborating cancer experts include the world’s leading cancer research charity, Cancer Research UK, and pioneering researchers from several of the world’s top universities, including Cambridge, Imperial College London and Oxford.

OUR ADVISORS

Steered by an exemplary team of internationally recognised clinicians and scientists, and chaired by Sir John Bell (Regius Professor of Medicine University of Oxford), our Scientific Advisory Board comprises – Prof. Chas Bountra (Oxford), Prof. Johann DeBono (London), Prof. William Gallagher (Dublin), Prof. Steve Jackson (Cambridge), Prof. Peter Johnson (Southampton), Prof. David Kerr (Oxford), Prof. Michael O’Dwyer (Galway), Dr. Anthony Quinn (Boston), & Prof. John Robertson (Nottingham).

OUR NAME

Carrick Therapeutics’ aim is to create the leading European based oncology company. The name Carrick means ‘rock’ in Irish to emphasize our strong foundation of like-minded scientists, collaborators and investors, and the vision to build a durable world-class company. Carrick Therapeutics has an ambitious patient focused vision to serve cancer patients around the world by the introduction of ground breaking cancer therapies that will transform the way cancer is treated.

OUR INVESTORS

We are backed by some of the most eminent providers of early stage capital, including ARCH Ventures, Woodford Investment Management, Cambridge Enterprise, Cambridge Innovation Capital, Evotec, Google Ventures, and Lightstone Ventures, all of whom have impeccable track records of accelerating the development of cutting edge science into new therapies.